These 3 drugs combine for $10B in annual sales. Yes, $10B.
ADP334 about to replace all 3.
Q4 2013 8 $994,020 -2.71% 1,568 -4.85%
Q3 2013 8 $1,021,678 2.60% 1,648 2.42%
Q2 2013 8 $995,800 2.76% 1,609 1.19%
Q1 2013 8 $969,058 3.58% 1,590 2.51%
Yes with combined annual revenue of $10B annually between humira, enbrel, and remicade its no wonder adp334 is number one. Adp334 has potential to become standard of care replacing all others for treatment of anti inflammatory conditions.
Whether it's selling 40% of his shares at $5.85, a secondary at $5.50 bailing out Deerfield shorts, a secondary at $4.81 bailing out who knows who yet, rest assured any rally will be short lived.
When does the retail investor get a bailout Jack?
Unless you are short where a trip to $3.20 and lower seems inevitable.
Enbrel used to treat five long-term inflammatory diseases: moderate to severe rheumatoid arthritis (RA), adult chronic moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy, psoriatic arthritis, moderate to severe juvenile idiopathic arthritis (JIA), and ankylosing spondylitis (AS). It is injected daily with horrid side effects.
Sales by quarter
Q4 2013 $1,189,844
Q3 2013 $1,172,679
Q2 2013 $1,147,929
Q1 2013 $1,075,249
In talking to my friend in Manhattan, these talks were likely initiated early 2014 however many major players were in a very poor position at the time when there were 67 million shorts sitting oh so comfortably. News was to be released but higher powers insisted a blackout. Magically over the course of a year, short interest plummeted coincidentally with a drastic drop in price per share from $8 to $3.32. Jack has always had a soft spot in his heart of hearts for shorts anyhow. Now as talks become more intense and time is of the essence, ARNA magically rises 75% to a more appropriate valuation from which negotiating leverage can be attained. I believe PI data although excellent and compelling was simply context for which to return the price to a more normal valuation. We should see ARNA return to $8 and be acquired for $12 to $15 range this year. Important shorts have already covered under the cloak of darkness over the course and convenience of 1 full year.
Jack what the #$%$ is the matta with you? Are you still excited ol' chap? Please tell us again how excited you are so we can revisit $2 range yet again despite pipeline despite milestone payments and cash in bank. Jack you are as worthless as you are senile and all of wall street is laughing at you and you alone.
Yes people. Orex a company withonly a generic weight loss combo drug and no patents or pipeline to speak of is equal in value to Arena a company with unlimited patents and multiple drug candidates.
What we have here is a failure in leadership period. Jack's inability to sell these points to Wall Street and to retail and institutional investors has ultimately given us a share price of $3.50 down from a high of $13.50 2 years previously. It is so sad that Arena was better off without FDA approval.
Don't forget the media blackout on all talks of arena buyout that came from higher ups at CNBC. The clips all disappeared soon after they were broadcast. Fast money hosts mentioned buy out at $18. I know first hand that execs told the hosts to gag it and no more mention of arena and buyouts
I guess we will revisit $3.20 after cc next week given that arena never ever goes up following a cc.
Irrelevant as the price mearly bounced from a 104 week low of $3.20. Miserable stock performance per se. Poor execution on behalf of Arena mgmt over 12 plus years and more recently Eisai whose marketing problems began years ago with Aricept. Aricept in the hands of Eisai alone nearly flopped. Enter Pfizer and Aricept became world's best seller for many years.
Eisai's efforts are amateurish and you would think they would learn from the mistakes of past.
and finally, ADP811 for pulmonary hypertension. Oh yeah, and then there's Belviq...
$10B market cap quickly.
I have been trading this stock for more years than I care to admit but this here run of strength bodes well for longs as something is cooking in the backround for sure. This is not just a simple PI PR people. This is more.
This gives ARNA a market cap of at least $10B on market potential alone!
Why is it any time ARNA makes a recovery in price Jack steps in and immediately squashes any and all hope for the retail investor?
No later than 1 week after great news the retail investor was met with insider selling and yes, wait for it, a share offering.
So is it back to $3.50 again Jack until next year? Do you play for the Chicago Cubs?
Jack promised news at year's end. With 2 days left dare I say he is a liar and a thief?
Welcome to 2015!